Zeitschriftenartikel zum Thema „Philip Johnson Associates“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-43 Zeitschriftenartikel für die Forschung zum Thema "Philip Johnson Associates" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Chohan, S., A. Kavanaugh, V. Strand, R. C. Chou, A. M. Mendelsohn, S. Rozzo und P. J. Mease. „AB0803 EFFICACY OF TILDRAKIZUMAB IN PsA: DAS28-CRP SCORES THROUGH WEEK 52“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1702–3. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3907.
Der volle Inhalt der QuelleJayne, D., P. Gavin, E. Allman, C. Di Poto, X. Tian, S. Hess, M. Ramaswamy et al. „OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 90.1–90. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1569.
Der volle Inhalt der QuellePray, C., N. Narula, E. C. Wong, J. K. Marshall, S. Rangarajan, S. Islam, A. Bahonar et al. „A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY“. Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (01.03.2023): 20–22. http://dx.doi.org/10.1093/jcag/gwac036.176.
Der volle Inhalt der QuelleRahman, P., C. T. Ritchlin, P. Helliwell, W. H. Boehncke, P. J. Mease, A. B. Gottlieb, S. Kafka et al. „FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 776–77. http://dx.doi.org/10.1136/annrheumdis-2020-eular.387.
Der volle Inhalt der QuelleRahman, P., P. J. Mease, A. Deodhar, A. Kavanaugh, S. D. Chakravarty, A. Kollmeier, Y. Liu, M. Shawi und C. Han. „OP0025 FACTORS ASSOCIATED WITH FATIGUE AND ITS IMPROVEMENT – A PRINCIPAL COMPONENT ANALYSIS OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS FROM GUSELKUMAB PHASE 3 TRIALS“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 18–19. http://dx.doi.org/10.1136/annrheumdis-2022-eular.895.
Der volle Inhalt der QuelleCoates, L. C., C. T. Ritchlin, L. Gossec, P. Helliwell, P. Rahman, E. C. Hsia, A. Kollmeier et al. „POS1024 GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 781–82. http://dx.doi.org/10.1136/annrheumdis-2021-eular.167.
Der volle Inhalt der QuelleCurtis, J., I. Mcinnes, D. D. Gladman, F. Yang, S. Peterson, P. Agarwal, A. Kollmeier et al. „POS1028 PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 784–85. http://dx.doi.org/10.1136/annrheumdis-2021-eular.432.
Der volle Inhalt der QuelleCoates, L., J. Ramírez, D. Mcgonagle, S. Aydin, M. Zimmermann, F. Nantel, M. Shawi, E. Rampakakis, P. Nash und P. J. Mease. „POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1137.1–1137. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2581.
Der volle Inhalt der QuelleMcgonagle, D., I. Mcinnes, A. Deodhar, G. Schett, P. J. Mease, M. Shawi, S. Kafka et al. „AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1701.2–1701. http://dx.doi.org/10.1136/annrheumdis-2020-eular.836.
Der volle Inhalt der QuelleCurtis, J., I. McInnes, P. Rahman, D. D. Gladman, F. Yang, S. Peterson, A. Kollmeier et al. „AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1563.2–1564. http://dx.doi.org/10.1136/annrheumdis-2022-eular.733.
Der volle Inhalt der QuelleGossec, L., D. Aletaha, P. Sewerin, A. Zabotti, F. Van den Bosch, M. Efficace, F. Lavie, M. Zimmermann, M. Sharaf und I. Mcinnes. „AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1761.1–1761. http://dx.doi.org/10.1136/annrheumdis-2023-eular.359.
Der volle Inhalt der QuelleSewerin, P., L. Dötsch, D. Truhm, D. Abrar und S. Nebelung. „THU0062 FUNCTIONAL MR IMAGING OF HUMAN MENISCUS IS ASSOCIATED WITH HISTOLOGICAL DEGENERATION“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 243. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6403.
Der volle Inhalt der QuelleCoates, L., I. Mcinnes, S. Aydin, M. Kishimoto, P. J. Mease, M. Shawi, M. Zimmermann, E. Rampakakis, F. Lavie und D. Mcgonagle. „POS0027 INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 220–21. http://dx.doi.org/10.1136/annrheumdis-2023-eular.122.
Der volle Inhalt der QuelleCurtis, J., I. Mcinnes, S. Peterson, P. Agarwal, F. Yang, A. Kollmeier, E. C. Hsia et al. „POS1026 GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 782.2–783. http://dx.doi.org/10.1136/annrheumdis-2021-eular.244.
Der volle Inhalt der QuelleNash, P., I. Mcinnes, C. T. Ritchlin, L. S. Tam, E. Soriano, M. Starr, E. Rampakakis et al. „AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1771–72. http://dx.doi.org/10.1136/annrheumdis-2023-eular.555.
Der volle Inhalt der QuelleBaraliakos, X., D. D. Gladman, S. D. Chakravarty, C. Gong, M. Shawi, E. Rampakakis, M. Kishimoto, E. Soriano und P. J. Mease. „POS0023 PERFORMANCE OF BASDAI VS. ASDAS IN EVALUATING AXIAL INVOLVEMENT IN PATIENTS WITH PSA TREATED WITH GUSELKUMAB: POOLED ANALYSIS OF TWO PHASE 3 STUDIES“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 217.2–218. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2761.
Der volle Inhalt der QuelleGladman, D. D., M. Starr, R. Ranza, A. M. Bravo Perdomo, M. Strauss, M. Shawi, C. Han, E. Rampakakis, A. Andrew Östör und P. J. Mease. „AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1765.1–1765. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1918.
Der volle Inhalt der QuelleMease, P. J., P. Foley, K. Reich, J. Bagel, M. Lebwohl, Y. W. Yang, M. Shawi et al. „POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 787–88. http://dx.doi.org/10.1136/annrheumdis-2021-eular.558.
Der volle Inhalt der QuelleOrbai, A. M., L. C. Coates, A. Deodhar, P. Helliwell, C. T. Ritchlin, A. Kollmeier, E. C. Hsia et al. „POS1029 GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 785–86. http://dx.doi.org/10.1136/annrheumdis-2021-eular.471.
Der volle Inhalt der QuelleCurtis, J., I. Mcinnes, P. Rahman, D. D. Gladman, F. Yang, S. Peterson, A. Kollmeier et al. „AB0888 Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1568–69. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1366.
Der volle Inhalt der QuelleCoates, L., P. Rahman, P. J. Mease, M. Shawi, E. Rampakakis, A. Kollmeier, X. L. Xu, S. D. Chakravarty, I. Mcinnes und L. S. Tam. „POS1067 DOMAINS CONTRIBUTING TO MINIMAL DISEASE ACTIVITY ACHIEVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 856–57. http://dx.doi.org/10.1136/annrheumdis-2022-eular.893.
Der volle Inhalt der QuelleRitchlin, C. T., P. J. Mease, W. H. Boehncke, J. Tesser, S. D. Chakravarty, E. Rampakakis, M. Shawi et al. „AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1779–80. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3238.
Der volle Inhalt der QuelleTillett, W., L. Coates, M. Vis, E. Soriano, J. F. Merola, M. Zimmermann, M. Shawi, M. Sharaf, P. Nash und P. Helliwell. „POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1131–32. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1690.
Der volle Inhalt der QuelleDu, Wenxuan, Adrian Johnston, Praful Nair, Jingyi Zhu, Khin Sandar Win, Bryan Zhou, Jude Phillip, Pei-Hsun Wu und Denis Wirtz. „Abstract 5949: Modulate TAM infiltration at cancer-immune interface by targeting at monocyte migration“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5949. http://dx.doi.org/10.1158/1538-7445.am2023-5949.
Der volle Inhalt der QuelleLippert, Anna L., Katherine A. Johnson, Cheri A. Pasch, Sean G. Kraus, Philip B. Emmerich, Linda Clipson, Kristina A. Matkowskyj, Wei Zhang und Dustin A. Deming. „Abstract 3198: Validation and analysis of cancer associated fibroblast subtype markers in metastatic colorectal cancer“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 3198. http://dx.doi.org/10.1158/1538-7445.am2022-3198.
Der volle Inhalt der QuelleGudikote, Jayanthi, Tina Cascone, Alissa Poteete, Piyada Sitthideatphaiboon, Sonia Patel, Yan Yang, Fahao Zhang et al. „Abstract 5733: Targeting nonsense-mediated decay restores p53 function in HPV-associated head and neck cancers“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 5733. http://dx.doi.org/10.1158/1538-7445.am2022-5733.
Der volle Inhalt der QuelleTaylor, P. C., K. De Vlam, A. G. Bushmakin, L. Fallon, J. F. Merola, J. C. Cappelleri, M. A. Hsu und P. J. Mease. „AB0838 IDENTIFYING MEDIATORS OF PAIN REDUCTION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION ASSOCIATED WITH PERIPHERAL ARTHRITIS, ENTHESITIS AND SKIN DISEASE“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1724–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1052.
Der volle Inhalt der QuelleJohnson, Katherine Anne, Anna L. Lippert, Sean G. Kraus, Grace E. McGrath, Philip B. Emmerich, Cheri A. Pasch, Linda Clipson, Kristina A. Matkowskyj, Wei Zhang und Dustin A. Deming. „Abstract 3533: Effects of tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib on cancer-associated fibroblast phenotypes in colorectal cancer“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 3533. http://dx.doi.org/10.1158/1538-7445.am2022-3533.
Der volle Inhalt der QuelleDale, David, Audrey Anna Bolyard, Emily Dick, Merideth L. Kelley, Vahagn Makaryan, Ramsey Johnson, Lu Gan und Sudha Parasuraman. „X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome“. Blood 130, Suppl_1 (07.12.2017): 995. http://dx.doi.org/10.1182/blood.v130.suppl_1.995.995.
Der volle Inhalt der QuelleChaudhuri, Somak, Dustin A. Deming, Cheri A. Pasch, Katherine A. Johnson, Chelsie K. Sievers und Philip B. Emmerich. „Abstract 1581: Colony-stimulating factor-1 receptor as a potential therapeutic target in pancreatic ductal adenocarcinoma“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 1581. http://dx.doi.org/10.1158/1538-7445.am2024-1581.
Der volle Inhalt der QuelleBrooks, J., A. Montgomery, N. Dalbeth, M. Sapsford, A. Cooper, R. Ngan Kee, V. Quincey et al. „OP0079 OMICRON VARIANT INFECTION IN INFLAMMATORY RHEUMATOLOGICAL CONDITIONS - OUTCOMES FROM A COVID-19 NAIVE POPULATION IN AOTEAROA NEW ZEALAND“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 54–55. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1749.
Der volle Inhalt der QuelleHilliard, Tyvette, Phillip Petrasko, Yueying Liu, Jing Yang, Marwa Asem, Jeff Johnson, Gifty Marfowaa et al. „Abstract 2189: The role of generational obesity on the ovarian metastatic niche“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 2189. http://dx.doi.org/10.1158/1538-7445.am2022-2189.
Der volle Inhalt der QuelleGossec, L., P. J. Mease, A. B. Gottlieb, A. Ogdie, D. Assudani, J. Coarse, B. Ink und L. C. Coates. „AB0778 ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1687.1–1687. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4204.
Der volle Inhalt der QuelleWahyuni, Anna Tri, Masfuri Masfuri und Liya Arista. „FAKTOR-FAKTOR YANG MEMPENGARUHI MORTALITAS PADA PASIEN DENGAN FRAKTUR COSTA: Literature Review“. Jurnal Keperawatan Widya Gantari Indonesia 6, Nr. 2 (20.07.2022): 157. http://dx.doi.org/10.52020/jkwgi.v6i2.4151.
Der volle Inhalt der QuelleMI KANG, YU, GIORGIO E. M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI et al. „1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58“. Diabetes 73, Supplement_1 (14.06.2024). http://dx.doi.org/10.2337/db24-1896-lb.
Der volle Inhalt der QuelleMI KANG, YU, GIORGIO E. M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI et al. „1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58“. Diabetes 73, Supplement_1 (14.06.2024). http://dx.doi.org/10.2337/db24-1895-lb.
Der volle Inhalt der QuelleGao, Xiang. „A ‘Uniform’ for All States?“ M/C Journal 26, Nr. 1 (15.03.2023). http://dx.doi.org/10.5204/mcj.2962.
Der volle Inhalt der QuelleGoggin, Gerard, und Christopher Newell. „Fame and Disability“. M/C Journal 7, Nr. 5 (01.11.2004). http://dx.doi.org/10.5204/mcj.2404.
Der volle Inhalt der QuelleFelton, Emma. „Brisbane: Urban Construction, Suburban Dreaming“. M/C Journal 14, Nr. 4 (22.08.2011). http://dx.doi.org/10.5204/mcj.376.
Der volle Inhalt der QuelleHarrison, Karey. „Building Resilient Communities“. M/C Journal 16, Nr. 5 (24.08.2013). http://dx.doi.org/10.5204/mcj.716.
Der volle Inhalt der QuelleLyons, Craig, Alexandra Crosby und H. Morgan-Harris. „Going on a Field Trip: Critical Geographical Walking Tours and Tactical Media as Urban Praxis in Sydney, Australia“. M/C Journal 21, Nr. 4 (15.10.2018). http://dx.doi.org/10.5204/mcj.1446.
Der volle Inhalt der QuelleRaffa, Taylor, Parker Chang, Babak Sarani und Susan Kartiko. „Surgical Stabilization of Rib Fractures: A Review of the Indications, Technique, and Outcomes“. Medical Research Archives 11, Nr. 11 (2023). http://dx.doi.org/10.18103/mra.v11i11.4694.
Der volle Inhalt der QuelleBrien, Donna Lee. „From Waste to Superbrand: The Uneasy Relationship between Vegemite and Its Origins“. M/C Journal 13, Nr. 4 (18.08.2010). http://dx.doi.org/10.5204/mcj.245.
Der volle Inhalt der Quelle